Brief: Arrivent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1B Study
23/06/2025 12:05
June 23 (Reuters) - Arrivent Biopharma Inc AVBP.O: ARRIVENT ANNOUNCES POSITIVE INTERIM FIRMONERTINIB MONOTHERAPY DATA FROM GLOBAL PHASE 1B STUDY IN EGFR PACC MUTANT NON-SMALL CELL LUNG CANCER AND PLANS TO ADVANCE INTO A GLOBAL PIVOTAL STUDY ARRIVENT BIOPHARMA- ENROLLMENT OF FIRST PATIENT IN A RANDOMIZED, GLOBAL PIVOTAL PHASE 3 STUDY IN FIRST-LINE PACC PATIENTS EXPECTED IN H2 2025 Source text: ID:nGNX96tMl7 Further company coverage: AVBP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ArriVent BioPharma
See all newsBrief: Arrivent Announces First Patient Dosed With Novel Tetravalent Muc16/Napi2b Dual Target Adc, Arr-002
US RESEARCH ROUNDUP-Allstate, Caribou Biosciences, Zscaler
U.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
ArriVent falls after lung cancer drug misses late-stage trial goal